Medical news
-
Providing guidance on product selection
There are several new treatment products for bleeding disorders available today and over the next couple of years, even more will likely become available to...
-
World Federation of Hemophilia product selection statement
The selection of safe, effective medicinal products is the responsibility of national regulatory and health agencies. In the case of clotting factor concentrates, whether plasma-derived...
-
WFH statement on end-product testing
End-product testing cannot be used to assure viral safety of clotting factor concentrates. The testing used for screening plasma for viral agents, whether performed on...
-
Zika virus
The World Health Organization (WHO) has declared the Zika virus a public health emergency of international concern. They define this as “an extraordinary event which is...
-
Electronic patient records and databases
Electronic patient records (EPRs) and databases are not new concepts for people with hemophilia. Generally, electronic patient records are developed as soon as patients are...
-
Data collection on a global scale
Collecting data from patients with hemophilia is important not only for advocacy purposes, but also to answer important questions about how hemophilia is managed in...
-
First recombinant von Willebrand Factor approved by FDA
The United States Food and Drug Administration (FDA) has approved Vonvendi, a recombinant von Willebrand Factor manufactured by Baxalta. The product is approved for on-demand...
-
Historical perspective on the treatment of hemophilia: Understanding the value of experience
As we enter into an era of increased scrutiny over healthcare costs and the associated benefits of providing certain treatment regimens, it has become quite...
-
A diverse and innovative program awaits: WFH 2016 World Congress
The WFH 2016 World Congress will be held in Orlando from July 24-28, 2016. It is a unique global platform to share experience and expertise...
-
Global Forum speakers highlight need for inhibitor surveillance
Inhibitors—antibodies to infused factor VIII or factor IX produced by the immune system, making treatment ineffective—are the foremost treatment complication faced by people with hemophilia...
